Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Data processing and quality evaluation of a boat-based mobile laser scanning system.

Vaaja M, Kukko A, Kaartinen H, Kurkela M, Kasvi E, Flener C, Hyyppä H, Hyyppä J, Järvelä J, Alho P.

Sensors (Basel). 2013 Sep 17;13(9):12497-515. doi: 10.3390/s130912497.

2.

Fluorescence-based high-throughput screening assay for drug interactions with UGT1A6.

Soikkeli A, Kurkela M, Hirvonen J, Yliperttula M, Finel M.

Assay Drug Dev Technol. 2011 Oct;9(5):496-502. doi: 10.1089/adt.2010.0349. Epub 2011 Mar 25.

PMID:
21438674
3.

Glucuronidation of racemic O-desmethyltramadol, the active metabolite of tramadol.

Lehtonen P, Sten T, Aitio O, Kurkela M, Vuorensola K, Finel M, Kostiainen R.

Eur J Pharm Sci. 2010 Nov 20;41(3-4):523-30. doi: 10.1016/j.ejps.2010.08.005. Epub 2010 Aug 24.

PMID:
20797434
4.

Glucuronidation of psilocin and 4-hydroxyindole by the human UDP-glucuronosyltransferases.

Manevski N, Kurkela M, Höglund C, Mauriala T, Court MH, Yli-Kauhaluoma J, Finel M.

Drug Metab Dispos. 2010 Mar;38(3):386-95. doi: 10.1124/dmd.109.031138. Epub 2009 Dec 10.

5.

UDP-glucuronosyltransferases in conjugation of 5alpha- and 5beta-androstane steroids.

Sten T, Kurkela M, Kuuranne T, Leinonen A, Finel M.

Drug Metab Dispos. 2009 Nov;37(11):2221-7. doi: 10.1124/dmd.109.029231. Epub 2009 Aug 6.

6.

Mutation analysis in UGT1A9 suggests a relationship between substrate and catalytic residues in UDP-glucuronosyltransferases.

Patana AS, Kurkela M, Finel M, Goldman A.

Protein Eng Des Sel. 2008 Sep;21(9):537-43. doi: 10.1093/protein/gzn030. Epub 2008 May 23.

PMID:
18502788
7.

The UDP-glucuronosyltransferases as oligomeric enzymes.

Finel M, Kurkela M.

Curr Drug Metab. 2008 Jan;9(1):70-6. Review.

PMID:
18220573
8.

Eudismic analysis of tricyclic sesquiterpenoid alcohols: lead structures for the design of potent inhibitors of the human UDP-glucuronosyltransferase 2B7.

Bichlmaier I, Kurkela M, Siiskonen A, Finel M, Yli-Kauhaluoma J.

Bioorg Chem. 2007 Oct;35(5):386-400. Epub 2007 Aug 15.

PMID:
17706742
9.

High throughput screening assay for UDP-glucuronosyltransferase 1A1 glucuronidation profiling.

Trubetskoy OV, Finel M, Kurkela M, Fitzgerald M, Peters NR, Hoffman FM, Trubetskoy VS.

Assay Drug Dev Technol. 2007 Jun;5(3):343-54.

PMID:
17638534
10.

The human UDP-glucuronosyltransferase: identification of key residues within the nucleotide-sugar binding site.

Patana AS, Kurkela M, Goldman A, Finel M.

Mol Pharmacol. 2007 Sep;72(3):604-11. Epub 2007 Jun 19.

11.

Potent inhibitors of the human UDP-glucuronosyltransferase 2B7 derived from the sesquiterpenoid alcohol longifolol.

Bichlmaier I, Kurkela M, Joshi T, Siiskonen A, Rüffer T, Lang H, Finel M, Yli-Kauhaluoma J.

ChemMedChem. 2007 Jun;2(6):881-9.

PMID:
17479992
12.

Isoform-selective inhibition of the human UDP-glucuronosyltransferase 2B7 by isolongifolol derivatives.

Bichlmaier I, Kurkela M, Joshi T, Siiskonen A, Rüffer T, Lang H, Suchanova B, Vahermo M, Finel M, Yli-Kauhaluoma J.

J Med Chem. 2007 May 31;50(11):2655-64. Epub 2007 May 3.

PMID:
17474732
13.

Interactions with other human UDP-glucuronosyltransferases attenuate the consequences of the Y485D mutation on the activity and substrate affinity of UGT1A6.

Kurkela M, Patana AS, Mackenzie PI, Court MH, Tate CG, Hirvonen J, Goldman A, Finel M.

Pharmacogenet Genomics. 2007 Feb;17(2):115-26.

PMID:
17301691
14.

Chiral distinction between the enantiomers of bicyclic alcohols by UDP-glucuronosyltransferases 2B7 and 2B17.

Bichlmaier I, Siiskonen A, Kurkela M, Finel M, Yli-Kauhaluoma J.

Biol Chem. 2006 Apr;387(4):407-16.

PMID:
16606339
15.

Identification of COMT and ErmC inhibitors by using a microplate assay in combination with library focusing by virtual screening.

Kreander K, Kurkela M, Siiskonen A, Vuorela P, Tammela P.

Pharmazie. 2006 Mar;61(3):247-8.

PMID:
16599271
16.

Kinetic characterization of the 1A subfamily of recombinant human UDP-glucuronosyltransferases.

Luukkanen L, Taskinen J, Kurkela M, Kostiainen R, Hirvonen J, Finel M.

Drug Metab Dispos. 2005 Jul;33(7):1017-26. Epub 2005 Mar 31.

17.
18.

Microplate screening assay to identify inhibitors of human catechol-O-methyltransferase.

Kurkela M, Siiskonen A, Finel M, Tammela P, Taskinen J, Vuorela P.

Anal Biochem. 2004 Aug 1;331(1):198-200. No abstract available.

PMID:
15246016
19.

Glucuronidation of oxidized fatty acids and prostaglandins B1 and E2 by human hepatic and recombinant UDP-glucuronosyltransferases.

Little JM, Kurkela M, Sonka J, Jäntti S, Ketola R, Bratton S, Finel M, Radominska-Pandya A.

J Lipid Res. 2004 Sep;45(9):1694-703. Epub 2004 Jul 1.

20.

An active and water-soluble truncation mutant of the human UDP-glucuronosyltransferase 1A9.

Kurkela M, Mörsky S, Hirvonen J, Kostiainen R, Finel M.

Mol Pharmacol. 2004 Apr;65(4):826-31.

21.

Glucuronidation of anabolic androgenic steroids by recombinant human UDP-glucuronosyltransferases.

Kuuranne T, Kurkela M, Thevis M, Schänzer W, Finel M, Kostiainen R.

Drug Metab Dispos. 2003 Sep;31(9):1117-24.

22.

Expression and characterization of recombinant human UDP-glucuronosyltransferases (UGTs). UGT1A9 is more resistant to detergent inhibition than other UGTs and was purified as an active dimeric enzyme.

Kurkela M, García-Horsman JA, Luukkanen L, Mörsky S, Taskinen J, Baumann M, Kostiainen R, Hirvonen J, Finel M.

J Biol Chem. 2003 Feb 7;278(6):3536-44. Epub 2002 Nov 14.

23.

Supplemental Content

Loading ...
Support Center